Presentations & Publications
Immunologic Mechanisms and Engineering Objectives: Case Study of Anti-PD-L1 x IL-15
PEGS Europe Virtual – November 11, 2020 Program: Advancing Bispecifics and Combination Therapy to the Clinic
Abstract: Targeting IL-15 delivery to PD-L1 Expressing Tumors with an Anti-PD-L1-IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity
Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020
Poster: Targeting IL-15 delivery to PD-L1 Expressing Tumors using an Anti-PDL1 x IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity
Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020
Abstract 1142: Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
The 62nd ASH Annual Meeting and Exposition – December 5-8, 2020
Abstract 2093: The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML
The 62nd ASH Annual Meeting and Exposition – December 5-8, 2020
Structure, Function, and Therapeutic Use of IgM Antibodies
Published in Antibodies – Special Issue Structure and Function of Antibodies
Clinical Challenges and Engineering Therapeutic Solutions: The Covid-19 Pandemic
Bioinsider – Therapeutic Pipeline for COVID-19, September 17, 2020
IgM Antibodies with Very Potent Agonism for DR5-Induced Apoptosis and as Anti-Tumor Agents
PEGS Boston Virtual – August 31-September 4, 2020
A Bispecific IgM Antibody Format for Enhanced T cell-Dependent Killing with Minimal Cytokine Release
AACR Virtual Annual Meeting II: June 22-24, 2020